BOSTON--(BUSINESS WIRE)--Click
to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is
developing innovative and proprietary treatments for exercise-associated
muscle cramps, nocturnal leg cramps, and spasms associated with severe
neuromuscular conditions, today announced that Nobel Laureate and
Scientific Co-Founder, Rod MacKinnon, M.D., and Chief Executive Officer,
Christoph Westphal, M.D., Ph.D., will ring the NASDAQ Stock Market
Closing Bell at the NASDAQ MarketSite in Times Square on Monday, June 1,
2015, at 4:00 p.m.
Drs. MacKinnon and Westphal will be joined by members of the Flex Pharma
management team, Board of Directors, colleagues and friends to celebrate
the progress the Company has made since its initial public offering.
Flex Pharma began trading on the NASDAQ Global Market on January 29,
2015.
This event will be broadcast on the major business networks and a live
webcast of the NASDAQ Closing Bell can be accessed at .
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for exercise-associated muscle
cramps, nocturnal leg cramps, and spasms associated with severe
neuromuscular conditions. In three randomized, blinded,
placebo-controlled, cross-over studies, Flex Pharma's proprietary
treatment has shown a statistically significant reduction in the
intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Contacts
Flex Pharma, Inc.Elizabeth Woo, 617-874-1829SVP, Investor
Relations & Corporate Communicationsirdept@flex-pharma.com
Help employers find you! Check out all the jobs and post your resume.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.